Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA224-1093  |   NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Summary

  • Phase 3
  • Male and Female Gender icon
  • 18+
    Age Range
  • 133
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Participants must have histologically confirmed Stage IV or recurrent Non-small Cell Lung Cancer (NSCLC) of non-squamous (NSQ) histology with no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
    1. Participants must have measurable PD-L1 ≥ 1% Tumor Cell (TC) score by the investigational PD-L1 immunohistochemistry (IHC) assay VENTANA PD-L1 (SP263) CDx Assay conducted by central laboratory during the screening period prior to randomization.
      1. Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria.
        1. Participants must have an Easter Cooperative Oncology Group (ECOG) performance status of ≤ 1 at screening.
          1. Participants must have a life expectancy of at least 3 months at the time of randomization.

            Exclusion Criteria

            Exclusion Criteria Icon
            • Participants must not be pregnant and/or breastfeeding.
              1. Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown EGFR, ALK, or ROS-1 status are excluded.
                1. Participants with known BRAFV600E mutations, that are sensitive to available targeted inhibitor therapy; participants with known activating rearranged during transfection (RET) mutations or neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations are excluded. Participants with unknown or indeterminate BRAF mutation, activating RET mutations or NTRK fusion gene alterations are eligible.
                  1. Participants must not have untreated central nervous system (CNS) metastases.
                    1. Participants must not have leptomeningeal metastases (carcinomatous meningitis).
                      1. Participants must not have concurrent malignancy requiring treatment.
                        1. Participants must not have an active autoimmune disease.
                          1. Participants must not have history of interstitial lung disease or pneumonitis that required oral or intravenous (IV) glucocorticoids to assist with management.
                            1. Participants must not have a history of myocarditis.
                              1. Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.
                                Additional Information *
                                • Other protocol-defined Inclusion/Exclusion criteria apply.

                                  Treatment Options

                                  Study Arms

                                  ASSIGNED INTERVENTION

                                  Study Arms

                                  Experimental: Arm A

                                  ASSIGNED INTERVENTION
                                  • Drug: Nivolumab, Relatlimab, Carboplatin, Pemetrexed, Cisplatin

                                  Study Arms

                                  Active Comparator: Arm B

                                  ASSIGNED INTERVENTION
                                  • Drug: Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin
                                  Take the first step to see if you Match to a Clinical Trial – Check if you qualify
                                  Check if you qualify
                                  Answer some questions about Your health to see if you may match to this trial
                                  Match to a Trial
                                  If you are a match, click on the study to see the list of study site locations
                                  Select a Study Site Location
                                  Select a study site location that is convenient for you
                                  Register
                                  Provide your contact details for the study site to connect with you.

                                  Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you